KCNMA1 and chondrosarcoma: Furthermore, they found that a KCa1.1 inhibitor effectively countered the chemoresistance of MG-63 and human chondrosarcoma SW-1353 spheroid models to paclitaxel, doxorubicin (DOX), and cisplatin, hinting at a novel therapeutic strategy through KCa1.1 inhibition to sensitize OS cells to chemotherapy [47].